Pfizer Launches Toviaz For Overactive Bladder
This article was originally published in PharmAsia News
Executive Summary
Pfizer launched 4mg and 8mg Toviaz tablets (fesoterodine fumarate), a muscarinic receptor antagonist with high selectivity on the bladder, March 15.